Clinical Trials Directory

Trials / Completed

CompletedNCT00925392

Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Keith A. Rodvold · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study is being performed to measure the amount of the antibiotic doripenem (study drug) found in the fluid and cells of the lung and blood after receiving three doses of doripenem. The major objectives of this research are to see how much and for how long doripenem gets into the fluids and cells of the lungs of healthy adult subjects.

Detailed description

The primary objective of this descriptive study is to determine and compare the plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) concentrations following multiple intravenous doses of doripenem in healthy, non-smoking adult subjects. In brief, each subject who qualifies for the study will be randomized to one of two dosing regimens: doripenem 500 mg or doripenem 1000 mg every 8 hours for a total of three intravenous doses. Each dose of doripenem will be administered as an intravenous infusion over 4 hours. Serial blood samples for determining plasma doripenem concentrations will be collected prior to and after the start of the intravenous infusion of the third doripenem dose. Each subject will undergo one standardized bronchoscopy with BAL in the outpatient bronchoscopy suite at one of four sampling times after the start of the intravenous infusion of the third doripenem dose. BAL collection will provide samples to determine drug concentration in ELF and AM. Safety will be assessed throughout the study by adverse event monitoring, clinical laboratory tests, and vital sign monitoring.

Conditions

Interventions

TypeNameDescription
DRUGDoripenemIntravenous 500 mg every (q) 8 hours for 3 doses
DRUGDoripenemIntravenous 1000 mg q 8 hours for 3 doses

Timeline

Start date
2009-06-01
Primary completion
2010-01-01
Completion
2010-01-01
First posted
2009-06-22
Last updated
2013-03-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00925392. Inclusion in this directory is not an endorsement.